Results 51 to 60 of about 34,947 (279)

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future

Reviews in Cardiovascular Medicine
This review aims to summarize the status and future directions of pediatric heart failure (HF) pharmacotherapy. Notably, managing HF in children presents unique challenges due to heterogeneous etiologies and a longstanding paucity of pediatric-specific ...
Bibhuti B Das
doaj   +1 more source

Heart failure with preserved ejection fraction: A short review of diagnosis and management [PDF]

КардиоСоматика
Around 64 million persons in the world have heart failure (HF). HF patients with left ventricle ejection fraction (LVEF) of ≥50% are classified as having HF with preserved ejection fraction (HFpEF).
Sidhi Laksono, Prita Saskya Prameswari
doaj   +1 more source

Assessing pulmonary congestion in HFpEF

European Heart Journal, 2019
Abstract
Elke Platz, Scott D Solomon
openaire   +2 more sources

Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction [PDF]

, 2019
Aims: Impaired left ventricular diastolic function leading to elevated left atrial pressures, particularly during exertion, is a key driver of symptoms and outcomes in heart failure with preserved ejection fraction (HFpEF). Insertion of an interatrial
Aytug, H, Bergmann, MW, Doughty, RN, Gustafsson, F, Hasenfuβ, G, Hausleiter, J, Hayward, C, Jondeau, G, Kaye, DM, Kolodziej, A, Lang, I, Malek, F, McKenzie, S, Penicka, M, Petrie, MC, Ponikowski, P, Post, M, Raake, P, REDUCE LAP-HF study investigators,, Rosenberg, M, Spelman, T, Trochu, J-N, Westenfeld, R   +22 more
core   +2 more sources

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Evaluation of Cardiorenal Metabolic Syndrome in Patients with Heart Failure with Preserved Ejection Fraction. How Aware Are We?

Sakarya Tıp Dergisi
Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened.
Dilan Damla Ozturk, Fatih Necip Arıcı, Cigdem Erhan, Bektaş Işık, Mehmet Can Erişen, Berçem Berent Kaya, Ugur Can Izlimek, Cahit Dincer, Ahmet Gazi Mustan, Çisem Yılmaz, Tayyibe Saler, Hilmi Erdem Sümbül, Erdinc Gulumsek, Hüseyin Ali Öztürk   +13 more
doaj   +1 more source

Aortic flow is abnormal in HFpEF

Wellcome Open Research, 2023
Aims Turbulent aortic flow makes the cardiovascular system less effective. It remains unknown if patients with heart failure with preserved ejection fraction (HFpEF) have disturbed aortic flow. This study sought to investigate advanced markers of aortic flow disturbances in HFpEF.
Mehmood, Z., Assadi, H., Li, R., Kasmai, B., Matthews, G., Grafton-Clarke, C., Sanz-Cepero, A., Zhao, X., Zhong, L., Aung, N., Skinner, K., Hadinnapola, C., Swoboda, P., Swift, A.J., Vassiliou, V.S., Miller, C., van der Geest, R.J., Peterson, S., Garg, P.   +18 more
openaire   +6 more sources

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.

PLoS ONE, 2021
Sudden death is the most common mode of mortality in patients with heart failure and preserved ejection fraction (HFpEF). Ventricular arrhythmias (VA) have been suspected as the etiology but the supporting evidence in patients with HFpEF is scarce.
Jae Hyung Cho, Derek Leong, Natasha Cuk, Joseph E Ebinger, Catherine Bresee, Sung-Han Yoon, Ashkan Ehdaie, Michael Shehata, Xunzhang Wang, Sumeet S Chugh, Eduardo Marbán, Eugenio Cingolani   +11 more
doaj   +1 more source